Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Consultants

Neither a doctor nor a teaching hospital

Research payments

$461,146

234 payments

Through program year 2025, Clinical Research Consultants is reported as receiving $461,146 in research payments, across 234 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $12,598 2
2023 Research $2,925 16
2022 Research $17,554 22
2021 Research $74,395 30
2020 Research $300,062 24
2019 Research $53,613 140

Breakdown

Who paid Research payments · program years 2019–2025
  1. Dynavax Technologies Corporation $220,210 29 payments
  2. Akebia Therapeutics Inc $155,620 148 payments
  3. Alnylam Pharmaceuticals Inc. $29,848 11 payments
  4. Alexion Pharmaceuticals, Inc. $29,067 7 payments
  5. Sanofi Pasteur Inc. $19,910 2 payments
  6. CSL Behring $5,152 34 payments
  7. Novartis Pharmaceuticals Corporation $1,339 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis $220,210 29 payments
  2. A Phase 1B, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease $120,397 7 payments
  3. Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) $33,703 138 payments
  4. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) $29,067 7 payments
  5. CYD12 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US $19,910 2 payments
  6. A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy $15,250 8 payments
  7. A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease $12,598 2 payments
  8. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $5,152 34 payments
  9. A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) $2,000 1 payment
  10. Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (Fo2rward-2) $1,519 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record